Exact(19)
Forty of 108 patients were treated according to the RAISE study protocol [ 15] (RAISE group).
In our cohort, treatment with IVIG + PSL, as described in the RAISE study, did not decrease the frequency of CS in high-risk patients.
Patients who were treated according to the RAISE study protocol were defined as the RAISE group and the others were defined as the conventional group.
In 2012, Kobayashi et al. reported the findings of a randomized, open-label, blinded-endpoints trial in which 248 high-risk patients participated (the RAISE study).
We also reported that treatment with IVIG + PSL as reported by the RAISE study did not decrease the frequency of CS in this study.
We also compared clinical characteristics of patients treated with the protocol of the Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease (RAISE) study (RAISE group) and with the conventional Intravenous immunoglobulin (IVIG) protocol (conventional group).
Similar(41)
Details of the GO-RAISE study have been reported.
Here we present the 104-week efficacy and safety findings from the GO-RAISE study.
Details of the GO-RAISE study design, along with complete patient inclusion criteria, have been previously published.
Braun J, Baraliakos X, Hermann K-GA, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study.
We previously reported results of the double-blind, randomised, placebo-controlled, Phase 3 GO-RAISE study, in which golimumab was evaluated in patients with active AS, through week 24 1 and week 104 2 and now report findings through the completion of the 5-year GO-RAISE trial.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com